Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming

Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble <em>Leishmania</em> antigens and modified with a TNF&alpha;-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis

“…67 However, even if a particular type of NP promotes a certain pathway of antigen processing, it does not mean the exclusion of the other alternative pathway of antigen presentation. 68 Consequently, PLGA-based NPs used in the present study may have presented encapsulated sLiAg through major histocompatibility complex (MHC) class I and II molecules, as shown by both CD4 + and CD8 + T cells activation. In contrast to observations in murine CL, where a polarized response is sufficient for protection 69 and a concomitant Th2 abrogates even strong Th1 function, 70,71 a mixed Th1/Th2 response is essential for protection against VL.…”

Multi-scale approach for modeling stability, aggregation, and network formation of nanoparticles suspended in aqueous solutions

“…[8][9][10][11][12][13] Nevertheless, numerous experimental and theoretical challenges associated with coupling the macroscopic properties, like thermal conductivity and viscosity, with the nanoscale input parameters of nanoparticle suspensions (nano-suspensions), such as NP size, particle volume fraction, and particle surface chemistry, limit their rational design aimed at specific applications. 14 In this paper, we present a multi-scale model which is able to predict the dynamic behavior of NPs dispersed in aqueous solutions, thereby bringing us closer to delineating guidelines for modulating the stability and aggregation of nano-suspensions.…”

Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates

“…To perform immunogenicity studies, antigen formulations were combined with an immunostimulant, we compared CpG oligonucleotide to MPLA adjuvant. CpG is a TLR-9 agonist which has pro-inflammatory activity 38 associated with the induction of humoral 39 , 40 and cell-mediated immune responses 41 , 42 through a Th1 polarization. 33 , 34 In addition, CpG is a clinically relevant adjuvant, and has recently been approved by the FDA for use in a prophylactic vaccine for hepatitis B.…”